Let's stand up to COVID-19
Results of the COLCORONA study published in The Lancet Respiratory Medicine
May 27, 2021
Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications
January 27, 2021
On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial.
The COLCORONA study manuscript is now available in the public domain.
Colcorona is a home-based clinical trial that determines whether short-term treatment with an existing medication reduces the risk of mortality and lung complications related to COVID-19.
It is a randomized, placebo-controlled study. It is double-blind - which means neither doctor nor patient will know whether you are taking the trial medication or a placebo.
United States: New York City Tri-State area, San Francisco, Los Angeles, Bakersfield, Downey, Miami, Jacksonville, Houston, Dallas, Phoenix, Yuma, Rochester, Tupelo, Greenville, Chapel Hill, Little Rock
Canada: Quebec, Ontario, British-Columbia
South Africa: Cape Town
Brazil: San Paolo
Greece: Athens, Kozani, Alexandroupoli, Elefsina, Patras
KEY TRIAL REQUIREMENTS
You must have been diagnosed with and currently have COVID-19
You must be 40 years old or over
Trial lasts 30 days from home
Daily intake of study medication or placebo
You must not be in hospital due to COVID-19
You must not be pregnant or breastfeeding
This clinical trial is supported by